Impact of ADMA (asymmetric dimethylarginine) on physiology with respect to diabetes mellitus and respiratory system BEAS-2B cells (human bronchial epithelial cells)

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 2, 2013, Pages 253-263

  Galal, Omneya ^a   Podlogar, Julia ^a   Verspohl, Eugen J ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

ADMA; diabetes; respiratory system

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ARGININE; CIGLITAZONE; GLUCOSE; HEXOKINASE; INSULIN; INTERLEUKIN 6; INTERLEUKIN 8; LOSARTAN; MACROPHAGE INFLAMMATORY PROTEIN 2; METFORMIN; N(G),N(G) DIMETHYLARGININE; NATEGLINIDE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VIDARABINE;

ANIMAL EXPERIMENT; ARTICLE; BRONCHUS MUCOSA; CELL DESTRUCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; DIABETOGENESIS; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; RADIOIMMUNOASSAY; RAT;

ANIMALS; ARGININE; BLOOD GLUCOSE; CELL LINE; CHEMOKINE CXCL2; DIABETES MELLITUS; EPITHELIAL CELLS; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTERLEUKIN-6; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; RESPIRATORY MUCOSA; TRACHEA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871721388     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01590.x     Document Type: Article

References (66)

1. Vallance P, et al,. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20: 60-62.
2. Boger RH, et al,. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atherosclerosis 2003; 4: 1-3.
3. Lin KY, et al,. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-992.
4. Mittermayer F, et al,. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus. Wien Klin Wochenschr 2005; 117: 816-820.
5. Sugai M, et al,. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr J 2007; 54: 303-309.
6. Bode-Boger SM, et al,. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med 2003; 8: 77-81.
7. Stuhlinger MC, Stanger O,. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab 2005; 6: 3-14.
8. Boger RH,. The pharmacodynamics of L-arginine. J Nutr 2007; 137: 1650-1655.
9. Corton JM, et al,. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995; 229: 558-565.
10. Fryer LG, et al,. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signalling pathways. J Biol Chem 2002; 277: 25226-25232.
11. Lee WH, Kim SG,. AMPK-dependent metabolic regulation by PPAR agonists. PPAR Res 2010; doi: 10.1155/2010/549101.
12. Kelly M, et al,. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 2004; 320: 449-454.
13. Wells SM, Holian A,. Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells. Am J Respir Cell Mol Biol 2007; 36: 520-528.
14. Wells SM, et al,. Elevated asymmetric dimethylarginine alters lung function and induces collagen deposition in mice. Am J Respir Cell Mol Biol 2009; 40: 179-188.
15. Klein E, et al,. Asymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma. Am J Physiol Lung Cell Mol Physiol 2010; 299: L816-L825.
16. Moller P, et al,. Effect of aging on free amino acids and electrolytes in leg skeletal muscle. Clin Sci 1979; 56: 427-432.
17. Vallance P, et al,. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
18. Meinitzer A, et al,. Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin Chim Acta 2007; 384: 141-148.
19. Kielstein JT, et al,. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl 2001; 78: S9-S13.
20. MacAllister RJ, et al,. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996; 11: 2449-2452.
21. Kielstein JT, et al,. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-177.
22. Kielstein JT, et al,. Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 2006; 62: 39-44.
23. Asfari M, et al,. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 1992; 130: 167-178.
24. Reddel RR, et al,. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 1988; 48: 1904-1909.
25. Kinnula VL, et al,. Primary and immortalized (BEAS 2B) human bronchial epithelial cells have significant antioxidative capacity in vitro. Am J Respir Cell Mol Biol 1994; 11: 568-576.
26. Polikandriotis JA, et al,. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanism. Arterioscler Thromb Vasc Biol 2005; 25: 1810-1816.
27. Yuen CY, et al,. Telmisartan inhibits vasoconstriction via PPARgamma-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res 2011; 90: 122-129.
28. Iwase M, et al,. Nateglinide, a non-sulfonylurea rapid insulin secretagogues, increases pancreatic islet blood flow in rats. Eur J Pharmacol 2005; 518: 243-250.
29. Colca JR, et al,. Ciglitazone, a hypoglycemic agent: early effects on the pancreatic islets of ob/ob mice. Metabolism 1988; 37: 276-280.
30. Blumentrath J, Verspohl EJ,. Effects of retinoids and thiazolidinediones on proliferation, insulin release, and -insulin mRNA and GLUT 2 transporter mRNA of INS1 cells. Cell Biochem Funct 2001; 19: 159-169.
31. Chu KY, Leung PS,. Angiotensin II type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young type 2 diabetic mice. Antioxid Redox Signal 2007; 9: 869-878.
32. Das UN, et al,. L-arginine, NO and asymmetrical dimethylarginine in hypertension and type II diabetes. Front Biosci 2011; 16: 13-20.
33. Siervo M, et al,. Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of asymmetric dimethylarginine (ADMA). Nutr Metab Cardiovasc Dis 2011; 21: 1-10.
34. Abbasi F, et al,. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type II diabetes mellitus. Am J Cardiol 2001; 88: 1201-1203.
35. Stuhlinger MC, et al,. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc 2002; 287: 1420-1426.
36. Newsholme P, et al,. Exercise and possible molecular mechanisms of protection from vascular disease and diabetes: the central role of ROS and nitric oxide. Clin Sci 2009; 118: 341-349.
37. Salehi A, et al,. Islet constitutive nitric oxide synthase: biochemical determination and regulatory function. Am J Physiol 1996; 270: 1634-1641.
38. Tsuura Y, et al,. Endogenous nitric oxide inhibits glucose-induced insulin secretion by suppression of phosphofructokinase activity in pancreatic islets. Biochem Biophys Res Commun 1998; 252: 34-38.
39. Panagiotidis G, et al,. Influence of nitric oxide synthase inhibition, nitric oxide and hydroperoxide on insulin release induced by various secretagogues. Br J Pharmacol 1995; 114: 289-296.
40. Schmidt HH, et al,. Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science 1992; 255: 721-723.
41. Laychock SG, et al,. L-arginine stimulates cyclic guanosine 3',5'-monophosphate formation in rat islets of Langerhans and RINm5F insulinoma cells: evidence for L-arginine:nitric oxide synthase. Endocrinology 1991; 129: 3043-3052.
42. Jones PM, et al,. Nitric oxide is not involved in the initiation of insulin secretion from rat islets of Langerhans. Diabetologia 1992; 35: 1020-1027.
43. Pueyo ME, et al,. Insulin secretion in rats with chronic nitric oxide synthase blockade. Diabetologia 1994; 37: 879-884.
44. Mazzaferri EL, et al,. Effects of gastric inhibitory polypeptide on leucine- and arginine-stimulated insulin release. Am J Physiol 1983; 245: 114-120.
45. Nishiki Y, et al,. Nitric oxide (NO) is involved in modulation of non-insulin mediated glucose transport in chicken skeletal muscles. Comp Biochem Physiol B Biochem Mol Biol 2008; 149: 101-107.
46. Moncada S, et al,. Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
47. Lajoix AD, et al,. A neuronal isoform of nitric oxide synthase expressed in pancreatic beta-cells controls insulin secretion. Diabetes 2001; 50: 1311-1323.
48. Li J, et al,. Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle. Am J Physiol 2004; 287: 834-841.
49. Lira VA, et al,. Nitric oxide increases GLUT4 expression and regulates AMPK signalling in skeletal muscle. Am J Physiol Endocrinol Metab 2007; 293: 1062-1068.
50. Zhang BB, et al,. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009; 9: 407-416.
51. Salt IP, et al,. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J 1998; 335: 533-539.
52. Guo H, et al,. Suppression effects of AICAR on insulin secretion involved in peroxisome proliferator-activated receptor gamma changes in INS-1 cells. J Endocrinol Invest 2010; 33: 465-471.
53. Chang TJ, et al,. Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K (ATP) channel and insulin secretion in rats. Diabetologia 2009; 52: 1112-1121.
54. Dufer M, et al,. Activation of the AMP-activated protein kinase enhances glucose-stimulated insulin secretion in mouse beta-cells. Islets 2010; 2: 156-163.
55. Xin HY, et al,. Regulation by DDAH/ADMA pathway of lipopolysaccharide- induced tissue factor expression in endothelial cells. Thromb Haemost 2007; 97: 830-838.
56. Chen M, et al,. ADMA induces monocyte adhesion via activation of chemokine receptors in cultured THP-1 cells. Cytokine 2008; 43: 149-159.
57. Yi L, et al,. Quantitation of L-arginine and asymmetric dimethylarginine in human plasma by LC-selective ion mode-MS for type II diabetes mellitus study. Chem Pharm Bull 2011; 59: 839-843.
58. Kuo CL, et al,. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 gene expression by 5-aminoimidazole-4- carboxamide riboside is independent of AMP-activated protein kinase. J Cell Biochem 2008; 103: 931-940.
59. Gutierrez DA, et al,. Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diab Rep 2009; 9: 26-32.
60. Gallagher EJ, et al,. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med 2010; 77: 511-523.
61. Hajri T, et al,. Regulation of adiponectin production by insulin: interactions with tumor necrosis factor-alpha and interleukin-6. Am J Physiol 2011; 300: 350-360.
62. Chen MF, et al,. Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II. J Vasc Res 2007; 44: 391-402.
63. Yang ZC, et al,. Asymmetric dimethylarginine impairs glucose utilization via ROS/TLR4 pathway in adipocytes: an effect prevented by vitamin E. Cell Physiol Biochem 2009; 24: 115-124.
64. Uetani K, et al,. Double-stranded RNA dependence of nitric oxide synthase 2 expression in human bronchial epithelial cell lines BET-1A and BEAS-2B. Am J Respir Cell Mol Biol 2001; 24: 720-726.
65. Asano K, et al,. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci U S A 1994; 91: 10089-10093.
66. Veresh Z, et al,. ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide productin by angiotensin II-NAD(P)H oxidase pathway. Hypertension 2008; 52: 960-966.